Trial Profile
A Randomized, Open-label, Single-center, Phase II Trial to Explore the Safety and Efficacy of GC1102 and Determine Its Optimal Dose After Intravenous Administration in HBV-related Liver Transplant Recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2022
Price :
$35
*
At a glance
- Drugs Lenvervimab (Primary)
- Indications Hepatitis B
- Focus Proof of concept; Therapeutic Use
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 29 Jun 2016 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.